Volume 12, Number 8—August 2006
Research
Antibody Response to Pneumocystis jirovecii
Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†
Table 2
Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia patients by CD4+ count and week of observation*
| Week | All patients |
CD4+ <50 cells/μL |
CD4+ >50 cells/μL |
|||
|---|---|---|---|---|---|---|
| n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | |
| Baseline (0) | 80 | 4.2 (3.1–5.8) | 54 | 4.2 (2.8–6.3) | 26 | 4.4 (2.5–7.6) |
| 1–2 | 25 | 8.0 (4.1–15.8) | 17 | 7.3 (3.0–17.8) | 8 | 9.9 (2.8–35.3) |
| 3–4 | 19 | 10.4 (4.7–23.1)† | 13 | 6.3 (2.4–16.4) | 6 | 30.4 (7.1–129.5)‡ |
| 5–6 | 18 | 3.7 (2.0–6.8) | 10 | 5.5 (2.0–15.0) | 8 | 2.3 (1.2–4.4) |
*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 vs. week 0, p<0.001 vs. weeks 1–2, and p<0.001 vs. weeks 5–6.
‡p<0.001 vs. week 0, p<0.001 vs. weeks 5–6, p<0.03 vs. weeks 3–4 in CD4+ <50 cells/μL group.
Page created: December 09, 2011
Page updated: December 09, 2011
Page reviewed: December 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.